Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2010-N-0420]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Fax written comments on the collection of information by December 4, 2014.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to 
                        *oira_submission@omb.eop.gov.*
                         All comments should be identified with the OMB control number 0910-0689. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd.; COLE-14526, Silver Spring, MD 20993-0002 
                        *PRAStaff@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Testing Communications on FDA/Center for Veterinary Medicine (CVM)-Regulated Products Used in Animals (21 U.S.C. 393 (d)(2)(D))—OMB Control Number 0910-0689—Reinstatement FDA is authorized by section 1003(d)(2)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(d)(2)(D)) to conduct educational and public information programs relating to the safety of CVM-regulated products. FDA must conduct needed research to ensure that such programs have the highest likelihood of being effective. FDA expects that improving communications about the safety of regulated animal drugs, feed, food additives, and devices will involve many research methods, including individual indepth interviews, mall-intercept interviews, focus groups, self-administered surveys, gatekeeper reviews, and omnibus telephone surveys. The information collected will serve three major purposes. First, as formative research it will provide critical knowledge needed about target audiences to develop messages and campaigns about the use of FDA-regulated products for use in animals. Knowledge of consumer and veterinary professional decision-making processes will provide the better understanding of target audiences that FDA needs to design effective communication strategies, messages, labels, and labeling. These communications will aim to improve public understanding of the risks and benefits of using regulated animal drugs, feed, food additives, and devices by providing users with a better context in which to place risk information more completely. Second, as initial testing, it will allow FDA to assess the potential effectiveness of messages and materials in reaching and successfully communicating with their intended audiences. Testing messages with a sample of the target audience will allow FDA to refine messages while still in the developmental stage. Respondents will be asked to give their reaction to the messages in either individual or group settings. Third, as evaluative research, it will allow FDA to ascertain the effectiveness of the messages and the distribution method of these messages in achieving the objectives of the message campaign. Evaluation of campaigns is a vital link in continuous improvement of communications at FDA. In the 
                    **Federal Register**
                     of June 16, 2014 (79 FR 34312) FDA published a 60-day notice requesting public comment on the proposed collection of information. One comment was submitted; however, it was not responsive to the four collection of information topics solicited and therefore is not discussed in this document. FDA estimates the burden of this collection of information based on recent prior experience with the various types of data collection methods described in this document: Table 1—Estimated Annual Reporting Burden 1
21 U.S.C. 393(d)(2)(D)
Number of 
                             respondents
Number of 
                             responses per  
                             respondent
Total annual responses
Average 
                             burden per  
                             response
Total hoursIndividual Indepth Interviews
360
1
360
0.75
270General Public Focus Group Interviews
288
1
288
1.5
432Intercept Interviews: Central Location
600
1
600
0.25
150Intercept Interviews: Telephone
2
                             10,000
1
10,000
0.08
800Self-Administered Surveys
2,400
1
2,400
0.25
600( print page 65406)Gatekeeper Reviews
400
1
400
0.50
200Omnibus Surveys
2,400
1
2,400
0.17
408Total (General Public)
16,448

16,448

2,860Veterinarian/Scientific Expert Focus Group Interviews
288
1
288
0.75
216Total (Veterinarians/Scientific Experts)
288
1
288

216Total (Overall)
16,736
1
16,736

3,0761
                         There are no capital costs or operating or maintenance costs associated with this collection of information.2
                         These are brief interviews with callers to test message concepts and strategies following their call-in request to an FDA Center 1-800 number.
 Annually, FDA projects about 30 studies with 16,736 respondents, using a variety of research methods and lasting an average of 0.17 hours each (varying from 0.08-1.5 hours). Dated: October 28, 2014. Leslie Kux, Assistant Commissioner for Policy.


[FR Doc. 2014-26141 Filed 11-3-14; 8:45 am] BILLING CODE 4164-01-P